Collaboration enhanced the productivity of Biogen's AAV production platform to help accelerate efforts to bring novel gene therapies to patients worldwideBOSTON, Jan. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of the gene therapy collaboration they announced with Biogen in May 2021. Together, the companies aimed to redefine the industry standard for manufacturing recombinant adeno ...

A big part of the allure of investing in small and mid-cap stocks is their potential to be worth much more in the future. After all, it's a lot more probable that a company that's only worth a few billion dollars will grow its business enough to double in value than it is for a company that's already worth hundreds of billions. But smaller stocks also come with more risk, as they're often unproven and not well-established businesses.Ginkgo Bioworks (DNA -0.57%) is a mid-cap company that has some promising l ...

Ginkgo Bioworks Holdings Inc. (NYSE:DNA) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET Company Participants Megan LeDuc - Manager of Investor Relations Jason Kelly - Founder, CEO & Director Mark Dmytruk - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Poon Mah - TD Cowen Derik Bruin - BofA Securities Michael Freeman - Raymond James E.V. Koslosky - Goldman Sachs Megan LeDuc Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 ____________________________________ ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2023 Earnings Conference Call August 9, 2023 5:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President, Corporate Development Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Steve Mah - Cowen Mark Massaro - BTIG Anna Marie Wagner Good evening. I am Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. I’ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. (Exact Name of Registrant as Specified ...

Financial Data and Key Metrics Changes - The company reported a net loss of $100 million in Q1 2023, compared to a net loss of $1 million in the same period last year, primarily due to increased operating expenses and a decline in Biosecurity revenue [43] - Adjusted EBITDA was negative $100 million, reflecting higher expenses in cell engineering and expected declines in Biosecurity revenue [43] - Capital expenditures (CapEx) for Q1 2023 were $19 million, with expectations for lower levels in subsequent quarters [43] Business Line Data and Key Metrics Changes - Cell Engineering revenue reached $34 million in Q1 2023, a 59% increase from Q1 2022, driven entirely by services revenue [40] - The Biosecurity business generated $47 million in revenue in Q1 2023, with over 20% coming from recurring sources such as federal and international contracts [40] - The company added 13 new cell programs, supporting a total of 97 active programs across 60 customers, up from 64 active programs in Q1 2022 [39] Market Data and Key Metrics Changes - The company is expanding its Biosecurity efforts internationally, having collected samples from flights originating in 72 countries [41] - The company noted that the tighter capital market is making it harder for start-up companies in non-biopharma biotech to access capital, extending deal close times [93] Company Strategy and Development Direction - The company is focused on improving its platform for customers, emphasizing the importance of customer feedback to enhance service offerings [34][60] - New service offerings include Ginkgo Microbe Services, Ginkgo Cell Therapy Services, Ginkgo AAV Services, and Ginkgo RNA Therapeutic Services, aimed at leveraging platform assets [81] - The company aims to treat biology as an engineering discipline, moving towards a success-only payment model for certain services to enhance customer trust [83] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the goal of adding 100 new cell programs in 2023, supported by a robust sales pipeline [66] - The company is navigating a challenging macroeconomic environment while focusing on cost structure and maintaining liquidity of $1.2 billion [44] - Management highlighted the importance of AI and large data sets in driving innovation within the biotech sector, positioning Ginkgo as a key player in this transformation [68] Other Important Information - The company is experiencing a significant shift in its Biosecurity business, moving from K-12 COVID testing services to more sustainable revenue sources [40] - The company has seen a significant reduction in stock-based compensation expenses due to the rolling off of prior RSUs [42] Q&A Session Summary Question: How do you feel about your original forecast of adding 100 projects for 2023? - Management expressed confidence in the forecast, citing a good pipeline and ongoing expansion in biosecurity programs [63][65] Question: Can you provide an overview of Ginkgo's AI and code-based strategy? - Management highlighted the importance of AI in generating large data assets and its relevance to customers across various industries [67][69] Question: How is Ginkgo leveraging its existing code base for new cell programs? - Management noted that leveraging existing data and infrastructure significantly aids in sales and project acceleration [72][73] Question: How does Ginkgo balance leveraging collective learning while ensuring client confidentiality? - Management stated that the focus is on broad reusability of certain components while ensuring that proprietary client information remains protected [75]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 GINKGO BIOWORKS HOLDINGS, INC. (Exact Name of Registrant as Specified ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40097 GINKGO BIOWORKS HOLDINGS, INC. (Exact name of Registrant as specified in its Charter) Delaware 87-2652913 (St ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Anna Marie Wagner - SVP, Corporate Development Jason Kelly - Co-Founder & CEO Mark Dmytruk - CFO Conference Call Participants Matthew Sykes - Goldman Sachs Rahul Sarugaser - Raymond James Tejas Savant - Morgan Stanley Steve Mah - Cowen Madeline - William Blair Mark Massaro - BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks. ...